Germany· DE-A57-f793384a47ed6d43

Fluomizin

A dequalinium product containing dequalinium chloride, registered in Germany by Pierre Fabre Pharma Gmbh. The same ATC class is registered in 9 of our 19 countries.

ATC G01AC05

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedFluomizinATCG01AC05REGISTER NO.DE-A57-f793384a47ed6d…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Dequalinium is registered in 9 of 19 countries.

Countries holding a registration under ATC G01AC05 (dequalinium), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 6 of them publish a price we can compare per daily dose

Dequalinium · ATC G01AC05

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Germany
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dequalinium costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Dequalinium · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$5.10
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

EMA Article 57 (European Union)
Active substance
Dequalinium Chloride
Manufacturer
Pierre Fabre Pharma Gmbh
Country
Germany (DE)
ATC code
G01AC05
ATC class
Dequalinium
Defined daily dose
10 mg, V
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Dequalinium in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dequalinium products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Fluomizin, Tonsillol
  • Belgium · Fluomizin
  • Bulgaria · Флуомизин
  • Czechia · Naxyl
  • Estonia · Donaxyl
  • Spain · Fluomizin
  • Finland · Donaxyl
  • France · Vablys
  • United Kingdom (Northern Ireland) · Fluomizin
  • Croatia · Fluomizin
  • Hungary · Fluomizin
  • Italy · Coryfin Gola, Dequadin
  • Lithuania · Donaxyl
  • Luxembourg · Fluomizin
  • Latvia · Donaxyl
  • Norway · Donaxyl
  • Poland · Fluomizin
  • Portugal · Fluomizin
  • Romania · Fluomizin
  • Sweden · Donaxyl
  • Slovenia · Fluomizin
  • Slovakia · Fluomizin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/761d2c45-9610-49c7-ac8c-ec9941374f3d
GET /v1/drugs/761d2c45-9610-49c7-ac8c-ec9941374f3d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Vaginal Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Dequalinium Chloride",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about dequalinium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.